Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

Richard Malley, John Devincenzo, Octavio Ramilo, Penelope H. Dennehy, H. Cody Meissner, William C. Gruber, Pablo J. Sanchez, Hasan Jafri, James Balsley, David Carlin, Steve Buckingham, Louis Vernacchio, Donna M. Ambrosino

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Thirty-five children <2 years of age mechanically ventilated for respiratory syncytial Virus (RSV) infection were randomized to receive an intravenous infusion of 15 mg/kg MEDI-493 or placebo. RSV concentration was measured in tracheal secretions by plaque assay before and at 24-h intervals after treatment. The reduction in tracheal RSV concentration from day 0 to day 1 (-1.7 ± 0.28 vs. -0.6 ± 0.21 log10 pfu/mL; P = .004) and from day 0 to day 2 (-2.5 ± 0.26 vs. -1.0 ± 0.41 log10 pfu/mL; P = .012) was significantly greater in the MEDI-493 group than in the placebo group. RSV concentration in nasal aspirates did not differ significantly between the groups. No significant differences were observed in the tracheal aspirate white blood cell count, or myeloperoxidase or eosinophilic cationic protein concentration, or in measures of disease severity between the groups. Thus, treatment with 15 mg/kg MEDI-493 intravenously was well-tolerated and significantly reduced RSV concentration in tracheal aspirates of children with respiratory failure due to RSV.

Original languageEnglish (US)
Pages (from-to)1555-1561
Number of pages7
JournalJournal of Infectious Diseases
Volume178
Issue number6
DOIs
StatePublished - 1998

Fingerprint

Antibodies, Monoclonal, Humanized
Respiratory Syncytial Viruses
Proteins
Placebos
Respiratory Syncytial Virus Infections
Leukocyte Count
Nose
Intravenous Infusions
Respiratory Insufficiency
Peroxidase
Therapeutics
Palivizumab

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Malley, R., Devincenzo, J., Ramilo, O., Dennehy, P. H., Meissner, H. C., Gruber, W. C., ... Ambrosino, D. M. (1998). Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. Journal of Infectious Diseases, 178(6), 1555-1561. https://doi.org/10.1086/314523

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. / Malley, Richard; Devincenzo, John; Ramilo, Octavio; Dennehy, Penelope H.; Meissner, H. Cody; Gruber, William C.; Sanchez, Pablo J.; Jafri, Hasan; Balsley, James; Carlin, David; Buckingham, Steve; Vernacchio, Louis; Ambrosino, Donna M.

In: Journal of Infectious Diseases, Vol. 178, No. 6, 1998, p. 1555-1561.

Research output: Contribution to journalArticle

Malley, R, Devincenzo, J, Ramilo, O, Dennehy, PH, Meissner, HC, Gruber, WC, Sanchez, PJ, Jafri, H, Balsley, J, Carlin, D, Buckingham, S, Vernacchio, L & Ambrosino, DM 1998, 'Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein', Journal of Infectious Diseases, vol. 178, no. 6, pp. 1555-1561. https://doi.org/10.1086/314523
Malley, Richard ; Devincenzo, John ; Ramilo, Octavio ; Dennehy, Penelope H. ; Meissner, H. Cody ; Gruber, William C. ; Sanchez, Pablo J. ; Jafri, Hasan ; Balsley, James ; Carlin, David ; Buckingham, Steve ; Vernacchio, Louis ; Ambrosino, Donna M. / Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. In: Journal of Infectious Diseases. 1998 ; Vol. 178, No. 6. pp. 1555-1561.
@article{1111c730117146f78fe6273b9ed8bf50,
title = "Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein",
abstract = "Thirty-five children <2 years of age mechanically ventilated for respiratory syncytial Virus (RSV) infection were randomized to receive an intravenous infusion of 15 mg/kg MEDI-493 or placebo. RSV concentration was measured in tracheal secretions by plaque assay before and at 24-h intervals after treatment. The reduction in tracheal RSV concentration from day 0 to day 1 (-1.7 ± 0.28 vs. -0.6 ± 0.21 log10 pfu/mL; P = .004) and from day 0 to day 2 (-2.5 ± 0.26 vs. -1.0 ± 0.41 log10 pfu/mL; P = .012) was significantly greater in the MEDI-493 group than in the placebo group. RSV concentration in nasal aspirates did not differ significantly between the groups. No significant differences were observed in the tracheal aspirate white blood cell count, or myeloperoxidase or eosinophilic cationic protein concentration, or in measures of disease severity between the groups. Thus, treatment with 15 mg/kg MEDI-493 intravenously was well-tolerated and significantly reduced RSV concentration in tracheal aspirates of children with respiratory failure due to RSV.",
author = "Richard Malley and John Devincenzo and Octavio Ramilo and Dennehy, {Penelope H.} and Meissner, {H. Cody} and Gruber, {William C.} and Sanchez, {Pablo J.} and Hasan Jafri and James Balsley and David Carlin and Steve Buckingham and Louis Vernacchio and Ambrosino, {Donna M.}",
year = "1998",
doi = "10.1086/314523",
language = "English (US)",
volume = "178",
pages = "1555--1561",
journal = "The Journal of infectious diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

AU - Malley, Richard

AU - Devincenzo, John

AU - Ramilo, Octavio

AU - Dennehy, Penelope H.

AU - Meissner, H. Cody

AU - Gruber, William C.

AU - Sanchez, Pablo J.

AU - Jafri, Hasan

AU - Balsley, James

AU - Carlin, David

AU - Buckingham, Steve

AU - Vernacchio, Louis

AU - Ambrosino, Donna M.

PY - 1998

Y1 - 1998

N2 - Thirty-five children <2 years of age mechanically ventilated for respiratory syncytial Virus (RSV) infection were randomized to receive an intravenous infusion of 15 mg/kg MEDI-493 or placebo. RSV concentration was measured in tracheal secretions by plaque assay before and at 24-h intervals after treatment. The reduction in tracheal RSV concentration from day 0 to day 1 (-1.7 ± 0.28 vs. -0.6 ± 0.21 log10 pfu/mL; P = .004) and from day 0 to day 2 (-2.5 ± 0.26 vs. -1.0 ± 0.41 log10 pfu/mL; P = .012) was significantly greater in the MEDI-493 group than in the placebo group. RSV concentration in nasal aspirates did not differ significantly between the groups. No significant differences were observed in the tracheal aspirate white blood cell count, or myeloperoxidase or eosinophilic cationic protein concentration, or in measures of disease severity between the groups. Thus, treatment with 15 mg/kg MEDI-493 intravenously was well-tolerated and significantly reduced RSV concentration in tracheal aspirates of children with respiratory failure due to RSV.

AB - Thirty-five children <2 years of age mechanically ventilated for respiratory syncytial Virus (RSV) infection were randomized to receive an intravenous infusion of 15 mg/kg MEDI-493 or placebo. RSV concentration was measured in tracheal secretions by plaque assay before and at 24-h intervals after treatment. The reduction in tracheal RSV concentration from day 0 to day 1 (-1.7 ± 0.28 vs. -0.6 ± 0.21 log10 pfu/mL; P = .004) and from day 0 to day 2 (-2.5 ± 0.26 vs. -1.0 ± 0.41 log10 pfu/mL; P = .012) was significantly greater in the MEDI-493 group than in the placebo group. RSV concentration in nasal aspirates did not differ significantly between the groups. No significant differences were observed in the tracheal aspirate white blood cell count, or myeloperoxidase or eosinophilic cationic protein concentration, or in measures of disease severity between the groups. Thus, treatment with 15 mg/kg MEDI-493 intravenously was well-tolerated and significantly reduced RSV concentration in tracheal aspirates of children with respiratory failure due to RSV.

UR - http://www.scopus.com/inward/record.url?scp=17344371596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344371596&partnerID=8YFLogxK

U2 - 10.1086/314523

DO - 10.1086/314523

M3 - Article

C2 - 9815203

AN - SCOPUS:17344371596

VL - 178

SP - 1555

EP - 1561

JO - The Journal of infectious diseases

JF - The Journal of infectious diseases

SN - 0022-1899

IS - 6

ER -